Skip to main content
2024 Canadian Cardiovascular Congress Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Handout
Handout
Networking
Networking
On-Demand
On-Demand
Early Career Involvement
Early Career Involvement
Back

YEAR IN REVIEW

YEAR IN REVIEW FOR THE CLINICAL CARDIOLOGIST: CLINICAL CARDIOLOGY

334 - HCM CHALLENGES

Saturday, October 26, 2024
11:30 AM – 11:45 AM PT
Room: 211
• HCM
I. 54 yr. asymptomatic male marathon runner with HCM Dx age 30 yrs.
Stress echo normal 16 METS with rest LVOT gradient 25 mmHg & peak exercise LVOT gradient 110 mmHg
a. Any role for BB & calcium channel blocker?
b. LGE 20% on CMR?
c. Genetic screening routinely for “everyone”

II. 39 yr. male symptomatic hockey player
Stress echo significant dyspnea at 16 METS with rest LVOT gradient 25 mmHg & peak exercise LVOT gradient 110 mmHg
a. BB or calcium blocker
b. Disopyramide
c. Myosin inhibitor
d. Septal reduction therapy – alcohol ablation vs. surgery
Disclosure(s):
Kevin Ong, MD FRCPC: Bristol Myers Squibb: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing)

    Presenter(s)

  • Kevin Ong, MD, FRCPC, FACC, FASE

    Clinical Assistant Professor
    Division of Cardiology, University of British Columbia
    St. Paul's Hospital, University of British Columbia